Form D · Biotechnology
GlucoTrack, Inc.
Rutherford, NJ · CIK 0001506983
Offering snapshot reported May 8, 2024 · SEC filing
- Reported sold
- $500K Offering amount: $500K
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 22, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 8, 2024 | Initial | $500,000 | No comparison | 9 | SEC filing |
| Feb 28, 2020 | Initial | $15,000,000 | No comparison | 1 | SEC filing |
| Dec 11, 2017 | Initial | $425,000 | No comparison | 6 | SEC filing |
| Jun 28, 2017 | Amendment | $11,003,800 | $4,771,000vs Jan 20, 2017 | 96 | SEC filing |
| Jan 20, 2017 | Amendment | $6,232,800 | $5,099,800vs Apr 18, 2016 | 78 | SEC filing |
| Apr 18, 2016 | Initial | $1,133,000 | No comparison | 17 | SEC filing |
| Sep 12, 2014 | Initial | $3,036,000 | No comparison | 31 | SEC filing |
| Mar 28, 2013 | Amendment | $7,455,399 | $6,300,000vs Dec 3, 2012 | 89 | SEC filing |
| Dec 3, 2012 | Initial | $1,155,399 | No comparison | 27 | SEC filing |
| Dec 27, 2010 | Initial | $3,566,047 | No comparison | 57 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-512729
Source: Form D, filed May 8, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jacob Bar Shalom | Executive |
| James Cardwell | Executive |
| Erin Carter | Director |
| Zvi Cohen | Director |
| Eran Cohen | Executive |
| Allen Danzig | Director |
| Philip Darivoff | Director |
| Israel Ehrlich | Director |
| Robert Fischell | Director |
| Avner Gal | Director, Executive |
| Joel L. Gold | Director |
| Paul Goode | Executive |
| John Graham | Director, Executive |
| Michael Hauck | Director |
| Eran Hertz | Executive |
| Jolie Kahn | Executive |
| Luis Malave | Director |
| David Malka | Executive |
| Eugene Naidis | Director, Executive |
| David Podwalski | Executive |
| Shimon Rapps | Director |
| Sami Sassoun | Executive |
| Revan Schwartz | Director |
| Leslie Seff | Director |
| Angela Strand | Director |
| Andrew Sycoff | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
301 Route 17 North Suite 800
Rutherford, NJ, 07070
Rutherford, NJ, 07070